Sionna cuts 46% of staff after cystic fibrosis trial failure, pivots to new drug combination on September 15, 2026 CF Cystic Fibrosis SION-2222 SION-451 SION-719 Sionna Therapeutics Trikafta workforce reduction +
MindMaze Trims Relief Staff and Aardvark Cuts Workforce Amid Prader-Willi Trial Problems on August 14, 2026 ARD-101 cardiac signals HERO trial Hyperphagia layoffs legacy operations MindMaze NeuroX merger organizational simplification Prader-Willi Syndrome Relief Therapeutics Study on Hold workforce reduction +
Sarepta delays Elevidys timeline amid FDA scrutiny on August 07, 2026 annualized Clinical Trials Elevidys Emergent BioSolutions Financial savings layoffs Muscular Dystrophy, Duchenne Pauses restructuring shipment United States Food and Drug Administration workforce reduction +
ADC Therapeutics cuts 17% of staff after 27 patient deaths in Zynlonta trial on June 25, 2026 Diffuse Large B-Cell Lymphoma Grade five rank layoffs LOTIS-5 Overall Survival patient deaths Progression-Free Survival reorganization TEAEs therapeutic autologous dendritic cells workforce reduction Zynlonta +
Valneva to cut up to 15% of jobs as reduced travel hits vaccine demand on May 14, 2026 Dukoral geopolitical factors guidance cut Ixchiq Ixiaro layoffs Lyme Disease operating costs restructuring travel Vaccines Valneva VLA15 workforce reduction +
Replimune Lays Off 60% of Workforce After Second FDA Rejection of RP1 Melanoma Drug on April 21, 2026 layoffs melanoma rejection Replimune RETINITIS PIGMENTOSA 1 United States Food and Drug Administration workforce reduction +
Theravance Biopharma Halves Workforce and Ends R&D After Phase 3 Failure on March 04, 2026 ampreloxetine CYPRESS study Phase 3 failure R&D shutdown Theravance Biopharma workforce reduction Yupelri +
Nxera Pharma to Cut 15% of Workforce in Japan and UK as Part of Restructuring Plan on November 19, 2025 GPCR pipeline Japan Nxera Pharma optimization Organization administrative structures profitability restructuring Surgical aspects UK workforce reduction +